The present study aims to investigate the feasibility and therapeutic potential of intravesically administered interleukin-12 mRNA-loaded lipid nanoparticles (IL-12 mRNA LNPs) for treatment of orthotopic bladder cancer.
What coping strategies related to mental adaptation to cancer are reported among patients with breast, lung, colorectal, prostate, and bladder cancers?
Systematic review reported according to the PRISMA guidelines.
Adolescents and young adults (AYA; 15–39 years) represent a distinct oncology population with specific biological and psychosocial needs. Despite growing awareness, AYA patients often face fragmented care between pediatric and adult settings, resulting in diagnostic delays, limited clinical trial access, and inadequate psychosocial support. In 2021, the AIOM-AIEOP AYA Working Group was established in Italy to promote awareness and address these challenges.
Synovial sarcoma (SS) is molecularly defined by the pathognomonic SS18::SSX fusion, a master epigenetic driver. While NTRK gene fusions are high-priority tissue-agnostic targets for TRK inhibitors like larotrectinib, their co-occurrence with established lineage-defining drivers in sarcomas is exceptionally rare and presents a therapeutic paradox.
For decades, the surgical management of non-small cell lung cancer (NSCLC) has been predominantly guided by anatomical staging. However, this traditional approach often overlooks the “fourth dimension” of cancer biology: time.
The follow up in early breast cancer represented a major challenging in oncology practice. Current guidelines are supported by evidence demonstrating no benefit of intensive surveillance.
Hereditary cancer genetics is increasingly recognized as an integral component of cancer care, contributing to treatment, early detection, and risk reduction strategies for patients and their relatives. In this context, several hereditary cancer programs, databases, recommendations, and guidelines have been implemented within the Italian National Health System and at hospital level.
Hereditary cancer genetics is increasingly recognized as an integral component of cancer care, contributing to treatment, early detection, and risk reduction strategies for patients and their relatives. In this context, several hereditary cancer programs, databases, recommendations, and guidelines have been implemented within the Italian National Health System and at hospital level.
Liquid biopsy has emerged as a valuable tool for detecting therapeutic targets and resistance mechanisms. This study evaluated the analytical performance and clinical utility of TruSight Oncology 500 ctDNA (TSO500) compared to the FDA-approved Guardant360 CDx (G360) in detecting actionable alterations in non-small cell lung cancer (NSCLC) patients progressing on targeted therapies.
Soft tissue and bone sarcomas may carry a considerable symptom burden, which typically worsens in the final weeks of life. To help clarify personalized palliative care needs, we investigated discrepancies in end-of-life management between patients with sarcoma and those with the most common carcinomas.